Zacks Research Estimates Editas Medicine FY2028 Earnings

Editas Medicine, Inc. (NASDAQ:EDIT) – Investment analysts at Zacks Research issued their FY2028 earnings per share estimates for shares of Editas Medicine in a research report issued to clients and investors on Monday, March 23rd. Zacks Research analyst Team expects that the company will post earnings of ($1.34) per share for the year. The consensus estimate for Editas Medicine’s current full-year earnings is ($2.71) per share.

Editas Medicine (NASDAQ:EDIT) last released its quarterly earnings data on Monday, March 9th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.21. Editas Medicine had a negative net margin of 395.02% and a negative return on equity of 389.73%. The firm had revenue of $24.74 million for the quarter, compared to analyst estimates of $8.77 million.

Several other equities research analysts have also recently weighed in on EDIT. Chardan Capital reiterated a “buy” rating and issued a $3.50 target price on shares of Editas Medicine in a research note on Monday, March 9th. Weiss Ratings reissued a “sell (e+)” rating on shares of Editas Medicine in a report on Wednesday, January 21st. TD Cowen restated a “buy” rating on shares of Editas Medicine in a research report on Monday, March 9th. JonesTrading raised Editas Medicine from a “hold” rating to a “buy” rating and set a $8.00 target price for the company in a research report on Tuesday, March 10th. Finally, Robert W. Baird set a $6.00 price target on shares of Editas Medicine in a research note on Monday, March 9th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $5.30.

Editas Medicine Trading Up 2.6%

Shares of Editas Medicine stock opened at $2.40 on Tuesday. Editas Medicine has a 1-year low of $0.91 and a 1-year high of $4.54. The firm has a fifty day simple moving average of $2.09 and a 200-day simple moving average of $2.56. The stock has a market capitalization of $234.89 million, a price-to-earnings ratio of -1.27 and a beta of 2.16.

Institutional Trading of Editas Medicine

Hedge funds have recently modified their holdings of the company. Captrust Financial Advisors acquired a new stake in shares of Editas Medicine during the second quarter worth about $26,000. StoneX Group Inc. bought a new stake in Editas Medicine during the 4th quarter worth approximately $33,000. Victory Capital Management Inc. acquired a new stake in Editas Medicine during the 3rd quarter worth approximately $36,000. Sei Investments Co. bought a new position in Editas Medicine in the third quarter valued at approximately $46,000. Finally, Baader Bank Aktiengesellschaft acquired a new position in shares of Editas Medicine in the third quarter valued at approximately $50,000. 71.90% of the stock is currently owned by institutional investors and hedge funds.

About Editas Medicine

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.